Profile data is unavailable for this security.

About the company

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

  • Revenue in USD (TTM)23.20bn
  • Net income in USD7.69bn
  • Incorporated1987
  • Employees10.00k
  • Location
    Gilead Sciences Inc333 LAKESIDE DRFOSTER CITY 94404United StatesUSA
  • Phone+1 (650) 574-3000
  • Fax+1 (650) 578-9264
  • Websitehttp://www.gilead.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
GILD:NSQ since
Cell Design Labs IncAnnounced07 Dec 201707 Dec 2017Announced4.12%567.00m
Data delayed at least 15 minutes, as of Oct 16 2018 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Celgene Corporation14.12bn4.07bn58.08bn7.47k15.9817.2612.644.115.283.6318.284.880.4430.91547.451,891,255.0012.7610.5514.5211.8196.4795.7128.8023.631.40--0.8610.0015.8018.75110.5323.6511.71--
Allergan plc16.16bn-4.19bn62.21bn17.80k--0.895319.983.85-12.52-5.2548.28209.970.13832.345.82907,679.80-3.42-3.28-3.65-3.5686.5679.93-24.72-26.440.84590.16150.2624--9.4021.93-457.69--45.77--
Biogen Inc12.87bn4.14bn66.67bn7.30k17.235.8413.535.1819.6514.1061.1457.970.56321.905.641,763,343.0018.9018.7022.0421.9086.4387.5233.5631.262.0719.910.32610.007.2117.340.267421.8949.69--
Bristol-Myers Squibb Co21.60bn3.30bn93.85bn23.70k28.737.6622.954.342.010.224813.187.550.6545.195.06911,392.4010.088.4714.1911.6770.4674.0915.4116.421.2824.170.37385.446.943.35-12.4314.7814.002.63
Gilead Sciences, Inc.23.20bn7.69bn95.40bn10.00k13.044.5610.464.115.851.6617.6616.720.36933.965.792,319,700.0012.2826.8514.5933.3480.6784.6033.2645.392.929.310.572112.47-14.0921.89-25.0431.328.24--
Eli Lilly And Co23.87bn1.77bn118.65bn40.66k66.0810.4334.894.971.68-0.153722.8510.650.57321.525.21587,231.604.257.516.0210.2372.9275.097.4113.051.0986.680.512677.167.770.2359-37.54-16.000.61681.20
Amgen, Inc.23.19bn8.46bn127.77bn20.80k16.848.8112.375.5112.023.6032.7922.970.31491.336.571,114,808.0011.499.3913.2010.7182.6880.9636.5031.043.1226.880.698238.42-0.61765.764.6213.21-0.736526.15
AbbVie Inc30.95bn6.82bn137.33bn29.00k21.45--16.144.444.294.0419.41-2.230.48114.735.811,067,104.0010.6510.1013.8213.0475.8177.2722.1319.670.71216.461.1074.3510.068.95-4.051.509.70--
Data as of Oct 16 2018. Currency figures normalised to Gilead Sciences Inc's reporting currency: US Dollar USD

Institutional shareholders

29.03%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 201894.11m7.26%
BlackRock Fund Advisorsas of 30 Jun 201867.00m5.17%
Capital Research & Management Co. (Global Investors)as of 30 Jun 201857.04m4.40%
SSgA Funds Management, Inc.as of 30 Jun 201854.44m4.20%
Parnassus Investmentsas of 30 Jun 201819.53m1.51%
Fidelity Management & Research Co.as of 30 Jun 201818.98m1.46%
Northern Trust Investments, Inc.as of 30 Jun 201816.82m1.30%
T. Rowe Price Associates, Inc.as of 30 Jun 201816.27m1.26%
Dodge & Coxas of 30 Jun 201816.26m1.25%
Geode Capital Management LLCas of 30 Jun 201815.93m1.23%
More ▼
Data from 30 Jun 2018 - 30 Jun 2018Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.